Trump says Iran war "close to over" amid hopes for more negotiations
NEW YORK - Our Bond, Inc. (NASDAQ:OBAI) announced today it has signed a commercial agreement valued at approximately $250,000 with one of the world’s five largest pharmaceutical companies, according to a press release statement.
The agreement covers 5,000 of the pharmaceutical company’s 100,000 employees across various functions and locations in the United States. The pharmaceutical company has a market capitalization exceeding $300 billion, though Bond did not disclose its name.
The contract establishes a new annual recurring revenue stream for Bond, which provides an AI-powered personal security platform. The company stated the engagement includes a potential expansion pathway that could increase the cumulative contract value beyond $1 million over time, subject to additional agreements.The new revenue comes as Bond faces financial headwinds, with a market capitalization of just $29.11 million and revenue of $9.79 million over the last twelve months. The stock has declined 93.64% year-to-date and is trading near its 52-week low of $2.03, according to InvestingPro data, which shows the company is currently overvalued based on its Fair Value analysis. InvestingPro offers 16 additional exclusive tips about OBAI’s financial health and market positioning.
"Executing commercial agreements with global leaders is central to our global expansion and revenue growth strategy," said Doron Kempel, Bond’s founder and CEO. "We have been focused on adoption of the Bond services by the largest companies in the world, thus establishing a standard for all corporations to eventually follow."
The platform is designed to provide real-time preventative security protection for employees across different geographies and operating conditions. Bond stated its services are used by executives, family members, and various employee types including store, branch, lab, and clinic employees.
Bond, headquartered in New York City, operates in 28 countries and has supported more than 1.4 million security service requests, including over 10,000 emergencies, according to the company. The company stated it has invested more than $100 million in its technology, operations, and global expansion.
The pharmaceutical agreement represents Bond’s entry into a commercial relationship with what it describes as a global healthcare industry leader.
In other recent news, TG-17, Inc. has announced a change in its corporate name to Our Bond, Inc. This decision is part of the company’s strategy to align its brand identity with its expanding sales and marketing efforts. The name change is intended to enhance consistency in communications with corporate, customer, and investor audiences. These developments reflect the company’s focus on strengthening its market presence and brand recognition. The announcement did not include any updates on earnings or revenue results. No mergers or analyst ratings were mentioned alongside this name change. The company has not provided further details on how this rebranding will impact its future operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.